{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T20:44:28Z","timestamp":1777927468401,"version":"3.51.4"},"reference-count":9,"publisher":"SAGE Publications","issue":"14","license":[{"start":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T00:00:00Z","timestamp":1694563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J STD AIDS"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:p>We present a case of a 53-year-old person living with human immunodeficiency virus and a new diagnosis of latent tuberculosis. The patient had baseline suppressed HIV viral load on fixed dose combination dolutegravir\/abacavir\/lamivudine when once-weekly rifapentine 900\u00a0mg\/isoniazid 900\u00a0mg\/pyridoxine 25\u00a0mg was initiated for 12\u00a0weeks. An additional 50\u00a0mg dolutegravir dose, administered in the evenings, was added to the daily antiretroviral regimen for treatment duration secondary to rifapentine uridine diphosphate glucuronsyl transferase induction. Dolutegravir trough concentrations decreased during concurrent therapy with noted slight HIV viral load rebound. Upon completion of rifapentine use, and a return to dolutegravir 50\u00a0mg daily dose, the trough concentrations increased with a return to an undetectable viral load. We provide suggested dolutegravir dosing considerations with concomitant rifapentine use, not currently addressed in recommended guidelines.<\/jats:p>","DOI":"10.1177\/09564624231201666","type":"journal-article","created":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T10:02:51Z","timestamp":1694599371000},"page":"1075-1077","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Alternative dolutegravir dosing strategies with concurrent rifapentine utilized for latent tuberculosis treatment"],"prefix":"10.1177","volume":"34","author":[{"given":"Addison","family":"Taylor","sequence":"first","affiliation":[{"name":"Virginia Commonwealth University Health System, Richmond, VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Winthrop","sequence":"additional","affiliation":[{"name":"Virginia Commonwealth University Health System, Richmond, VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6124-7205","authenticated-orcid":false,"given":"Patricia","family":"Pecora Fulco","sequence":"additional","affiliation":[{"name":"Virginia Commonwealth University Health System, Richmond, VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,9,13]]},"reference":[{"key":"bibr1-09564624231201666","unstructured":"Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/adult-adolescent-arv\/guidelines-adult-adolescent-arv.pdf (accessed 5 September 2022)."},{"key":"bibr2-09564624231201666","doi-asserted-by":"publisher","DOI":"10.1093\/CID\/ciz256"},{"key":"bibr3-09564624231201666","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30032-1"},{"key":"bibr4-09564624231201666","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283612419"},{"key":"bibr5-09564624231201666","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00215-22"},{"key":"bibr6-09564624231201666","unstructured":"Imperial MZ, Luetkemeyer A, Dawson R, et al. DTG PK in people with HIV receiving daily 1HP for latent TB treatment (ACTG A5372). In: vConference on retrovirus and opportunistic infections, Denver, CO, February 12\u201316, 2022. Abstract 78. https:\/\/www.croiconference.org\/wp-content\/uploads\/sites\/2\/resources\/2022\/croi2022-abstract-ebook.pdf (accessed 6 September 2022)."},{"key":"bibr7-09564624231201666","doi-asserted-by":"publisher","DOI":"10.1097\/QAD0000000000003508"},{"key":"bibr8-09564624231201666","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1806554"},{"key":"bibr9-09564624231201666","doi-asserted-by":"publisher","DOI":"10.1093\/OFID\/ofy332"}],"container-title":["International Journal of STD &amp; AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09564624231201666","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09564624231201666","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09564624231201666","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:45:00Z","timestamp":1777675500000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09564624231201666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,13]]},"references-count":9,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1177\/09564624231201666"],"URL":"https:\/\/doi.org\/10.1177\/09564624231201666","relation":{},"ISSN":["0956-4624","1758-1052"],"issn-type":[{"value":"0956-4624","type":"print"},{"value":"1758-1052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,13]]}}}